Journal of Clinical Endocrinology & Metabolism, Vol 81, 1940-1945, Copyright © 1996 by Endocrine Society

ARTICLES

A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease

I Antonipillai, J Nadler, EJ Vu, S Bughi, R Natarajan and R Horton
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.

Earlier studies in diabetic animal models or ex vivo from diabetics suggest a deficiency in prostacyclin (PGI2) production and an increase in an alternate arachidonic acid metabolite, 12-hydroxyeicosatetraenoic acid (12-HETE), which stimulates angiogenesis, mitogenesis, and inhibits renin secretion. We studied the urinary excretion rate of 6- keto-PGF1 alpha (a stable metabolite of PGI2) and 12-HETE in controls and 42 noninsulin-dependent diabetes mellitus (NIDDM) patients with normal renal function and those with micro- or macroalbuminuria/hyporeninemic hypoaldosteronism (HH). The 2 eicosanoids were measured in urine using previously described high pressure liquid chromatography and RIA methods. Normal subjects and patients with NIDDM and microalbuminuria were infused with low dose calcium infusions that stimulate prostacyclin production in normal subjects. The PGI2 excretion rate of NIDDM patients with normal renal function was not different from that of controls (143 +/- 17 vs. 118 +/- 34 ng/g creatinine), but was reduced in those with microalbuminuria (75 +/- 10) and in macroalbuminuria patients (48 +/- 7; P < 0.01). In contrast, 12-HETE was increased in diabetics with normal renal function as well as in those with micro- or macroalbuminuria patients (69 +/- 18 vs. 250 +/- 62 vs. 226 +/- 60 and 404 +/- 131 ng/g creatinine; P < 0.01). Calcium did not stimulate PGI2, but increased 12-HETE in diabetics with microalbuminuria in contrast to levels in normal subjects. HH patients excreted less PGI2 (as previously reported), but had increased 12-HETE. HETE/PGI2 ratios further demonstrated these changes in the various groups. In a nondiabetic hypertensive microalbuminuria group, 12-HETE excretion was normal (73 +/- 28 ng/g creatinine). We conclude that the lipoxygenase product 12-HETE is increased early in the diabetic process, whereas PGI2 production is progressively impaired in NIDDM. These changes may play a role in the vascular disease of diabetes and partially explain the HH syndrome.

This article has been cited by other articles:

				M. H. Nagelin, S. Srinivasan, J. L. Nadler, and C. C. Hedrick Murine 12/15-Lipoxygenase Regulates ATP-binding Cassette Transporter G1 Protein Degradation through p38- and JNK2-dependent Pathways J. Biol. Chem., November 6, 2009; 284(45): 31303 - 31314. [Abstract] [Full Text] [PDF]

				M. A. Reddy, S. Sahar, L. M. Villeneuve, L. Lanting, and R. Natarajan Role of Src Tyrosine Kinase in the Atherogenic Effects of the 12/15-Lipoxygenase Pathway in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 387 - 393. [Abstract] [Full Text] [PDF]

				E. M. Abdel-Rahman, P. M. Abadir, and H. M. Siragy Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1473 - R1478. [Abstract] [Full Text] [PDF]

				M. H. Nagelin, S. Srinivasan, J. Lee, J. L. Nadler, and C. C. Hedrick 12/15-Lipoxygenase Activity Increases the Degradation of Macrophage ATP-Binding Cassette Transporter G1 Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1811 - 1819. [Abstract] [Full Text] [PDF]

				Z.-G. Xu, H. Yuan, L. Lanting, S.-L. Li, M. Wang, N. Shanmugam, M. Kato, S. G. Adler, M. A. Reddy, and R. Natarajan Products of 12/15-Lipoxygenase Upregulate the Angiotensin II Receptor J. Am. Soc. Nephrol., March 1, 2008; 19(3): 559 - 569. [Abstract] [Full Text] [PDF]

				S. Xu, B. Jiang, K. A. Maitland, H. Bayat, J. Gu, J. L. Nadler, S. Corda, G. Lavielle, T. J. Verbeuren, A. Zuccollo, et al. The Thromboxane Receptor Antagonist S18886 Attenuates Renal Oxidant Stress and Proteinuria in Diabetic Apolipoprotein E-Deficient Mice Diabetes, January 1, 2006; 55(1): 110 - 119. [Abstract] [Full Text] [PDF]

				Z.-G. Xu, L. Lanting, N. D. Vaziri, Z. Li, L. Sepassi, B. Rodriguez-Iturbe, and R. Natarajan Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney: Reversal by Angiotensin II Type 1 Receptor Blockade Circulation, April 19, 2005; 111(15): 1962 - 1969. [Abstract] [Full Text] [PDF]

				Y.-S. Kim, Z.-G. Xu, M. A. Reddy, S.-L. Li, L. Lanting, K. Sharma, S. G. Adler, and R. Natarajan Novel Interactions between TGF-{beta}1 Actions and the 12/15-Lipoxygenase Pathway in Mesangial Cells J. Am. Soc. Nephrol., February 1, 2005; 16(2): 352 - 362. [Abstract] [Full Text] [PDF]

				S. S. Rich, D. W. Bowden, S. M. Haffner, J. M. Norris, M. F. Saad, B. D. Mitchell, J. I. Rotter, C. D. Langefeld, C. C. Hedrick, L. E. Wagenknecht, et al. A Genome Scan for Fasting Insulin and Fasting Glucose Identifies a Quantitative Trait Locus on Chromosome 17p: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study Diabetes, January 1, 2005; 54(1): 290 - 295. [Abstract] [Full Text] [PDF]

				R. Natarajan and J. L. Nadler Lipid Inflammatory Mediators in Diabetic Vascular Disease Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1542 - 1548. [Abstract] [Full Text] [PDF]

				M. S. Perassolo, J. C. Almeida, R. L. Pra, V. D. Mello, A. L. Maia, C. C. Moulin, J. L. Camargo, T. Zelmanovitz, M. J. Azevedo, and J. L. Gross Fatty Acid Composition of Serum Lipid Fractions in Type 2 Diabetic Patients With Microalbuminuria Diabetes Care, March 1, 2003; 26(3): 613 - 618. [Abstract] [Full Text] [PDF]

				M. A. Reddy, S. G. Adler, Y.-S. Kim, L. Lanting, J. Rossi, S.-W. Kang, J. L. Nadler, A. Shahed, and R. Natarajan Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells Am J Physiol Renal Physiol, November 1, 2002; 283(5): F985 - F994. [Abstract] [Full Text] [PDF]

				M. A. Reddy, P.-R. Thimmalapura, L. Lanting, J. L. Nadler, S. Fatima, and R. Natarajan The Oxidized Lipid and Lipoxygenase Product 12(S)-Hydroxyeicosatetraenoic Acid Induces Hypertrophy and Fibronectin Transcription in Vascular Smooth Muscle Cells via p38 MAPK and cAMP Response Element-binding Protein Activation. MEDIATION OF ANGIOTENSIN II EFFECTS J. Biol. Chem., March 15, 2002; 277(12): 9920 - 9928. [Abstract] [Full Text] [PDF]

				G. Hardy, F. Stanke-Labesque, M. Peoc'h, A. Hakim, P. Devillier, F. Caron, S. Morel, P. Faure, S. Halimi, and G. Bessard Cysteinyl Leukotrienes Modulate Angiotensin II Constrictor Effects on Aortas From Streptozotocin-Induced Diabetic Rats Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1751 - 1758. [Abstract] [Full Text] [PDF]

				D. Gonzalez-Nunez, J. Claria, F. Rivera, and E. Poch Increased Levels of 12(S)-HETE in Patients With Essential Hypertension Hypertension, February 1, 2001; 37(2): 334 - 338. [Abstract] [Full Text] [PDF]

				M. K. Patricia, R. Natarajan, A. N. Dooley, F. Hernandez, J.-L. Gu, J. A. Berliner, J. J. Rossi, J. L. Nadler, R. S. Meidell, and C. C. Hedrick Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells Circ. Res., April 13, 2001; 88(7): 659 - 665. [Abstract] [Full Text] [PDF]